1 McCusker ME, Coté TR, Clegg LX, et al. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998[J]. Cancer, 2002, 94(12): 3307-3312.
[2]
2 Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies[J]. Dis Colon Rectum, 1998, 41(1): 75-80.
6 Shankar S, Ledakis P, El Halabi H, et al. Neoplasms of the appendix: current treatment guidelines[J]. Hematol Oncol Clin North Am, 2012, 26(6): 1261-1290.
[7]
7 Ross A, Sardi A, Nieroda C, et al. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC[J]. Eur J Surg Oncol, 2010, 36(8): 772-776.
[8]
8 Smith JW, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan- Kettering Cancer Center experience[J]. Cancer, 1992, 70(2): 396-401.
[9]
9 Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach[J]. Ann Surg, 1994, 219(2): 112-119.
[10]
10 Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)[J]. Ann Surg Oncol, 2008, 15(2): 526-534.
